基于1816例卵巢癌转录组数据识别铂类和紫杉烷耐药预测生物标志物
本研究整合GEO和TCGA数据库的12个独立数据集共1816例浆液性卵巢癌肿瘤样本,以病理反应或无复发生存期定义治疗反应,比较应答者与非应答者基因表达差异。分析发现与铂类+紫杉烷耐药最强的8个基因,其中TFE3、NCOR2、PDXK、AKIP1、MARVELD1和AKIRIN2在独立验证集中得到验证,并建立在线接口用于未来生物标志物验证与排序。
要点
- 整合12个数据集1816例样本,识别铂类+紫杉烷耐药最强8个基因。
- 独立验证确认TFE3、NCOR2、PDXK、AKIP1、MARVELD1和AKIRIN2与化疗反应相关。
- 建立在线接口www.rocplot.org/ovar用于新生物标志物自动验证与排序。
核心结论
- 在浆液性卵巢癌中识别出与铂类+紫杉烷耐药相关的8个最强基因,其中6个在独立验证集中得到确认。
研究设计与样本
- 从GEO和TCGA数据库收集基因芯片数据,整合12个独立数据集共1816例肿瘤样本。
- 以病理反应或无复发生存期定义治疗反应,采用Mann-Whitney检验和ROC曲线检验比较应答者与非应答者。
- 建立独立验证集考察前8个基因与化疗反应的相关性,统计显著性设定为p<0.05。
主要发现
- 全数据库分析中与铂类+紫杉烷反应最强的8个基因为AKIP1(p=1.60E-08,AUC=0.728)、MARVELD1(p=2.70E-07,AUC=0.712)、AKIRIN2(p=2.60E-07,AUC=0.704)、CFL1(p=8.10E-08,AUC=0.694)、SERBP1(p=8.10E-07,AUC=0.684)、PDXK(p=1.30E-04,AUC=0.634)、TFE3(p=7.90E-05,AUC=0.631)和NCOR2(p=1.90E-03,AUC=0.611)。
- 独立验证确认TFE3(p=0.012,AUC=0.718)、NCOR2(p=0.048,AUC=0.671)、PDXK(p=0.019,AUC=0.702)、AKIP1(p=0.002,AUC=0.773)、MARVELD1(p=0.044,AUC=0.675)和AKIRIN2(p=0.042,AUC=0.676)与化疗反应相关。
- 建立在线接口www.rocplot.org/ovar,可自动化验证和排序新的生物标志物候选。
关键数值与推荐
- 治疗反应定义基于病理反应或无复发生存期。
- 统计显著性设定为p<0.05。
- 独立验证集中TFE3、NCOR2、PDXK、AKIP1、MARVELD1和AKIRIN2与化疗反应显著相关。
临床怎么用
- 识别出的生物标志物候选可用于未来开发预测铂类和紫杉烷耐药的风险分层工具。
- 在线接口可供临床研究者自动验证和排序新的生物标志物候选。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The first-line chemotherapy for ovarian cancer is based on a combination of platinum and taxane. To date, no reliable predictive biomarker has been recognized that is capable of identifying patients with pre-existing resistance to these agents. Here, we have established an integrated database and identified the most significant biomarker candidates for chemotherapy resistance in serous ovarian cancer. METHODS: Gene arrays were collected from the GEO and TCGA repositories. Treatment response was defined based on pathological response or duration of relapse-free survival. The responder and nonresponder cohorts were compared using the Mann-Whitney and receiver operating characteristic tests. An independent validation set was established to investigate the correlation between chemotherapy response for the top 8 genes. Statistical significance was set at p < 0.05. RESULTS: The entire database included 1816 tumor samples from 12 independent datasets. From analyzing all the genes for platinum + taxane response, we identified the eight strongest genes correlated to chemotherapy resistance: AKIP1 (p = 1.60E-08, AUC = 0.728), MARVELD1 (p = 2.70E-07, AUC = 0.712), AKIRIN2 (p = 2.60E-07, AUC = 0.704), CFL1 (p = 8.10E-08, AUC = 0.694), SERBP1 (p = 8.10E-07, AUC = 0.684), PDXK (p = 1.30E-04, AUC = 0.634), TFE3 (p = 7.90E-05, AUC = 0.631) and NCOR2 (p = 1.90E-03, AUC = 0.611). Of these, the independent validation confirmed TFE3 (p = 0.012, AUC = 0.718), NCOR2 (p = 0.048, AUC = 0.671), PDXK (p = 0.019, AUC = 0.702), AKIP1 (p = 0.002, AUC = 0.773), MARVELD1 (p = 0.044, AUC = 0.675) and AKIRIN2 (p = 0.042, AUC = 0.676). An online interface was set up to enable future validation and ranking of new biomarker candidates in an automated manner (www.rocplot.org/ovar). CONCLUSIONS: We compiled a large integrated database with available treatment and response information and used this to uncover new biomarkers of chemotherapy response in serous ovarian cancer.
引用
- Fekete JT, Ősz Á, Pete I, et al. Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients. Gynecol Oncol. 2020. PMID: 31973910. doi:10.1016/j.ygyno.2020.01.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。